A61K 2039/60
Characteristics by the carrier linked to the antigen
Official title: {characteristics by the carrier linked to the antigen}
A61K2039/60 (Characteristics by the carrier linked to the antigen) appears on 3,587 US grants and 5,733 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,587
- Published applications
- 5,733
- Assignees
- 2,102
- Inventors
- 8,975
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 6 | 0 |
| 1980 | 9 | 0 |
| 1981 | 14 | 0 |
| 1982 | 4 | 0 |
| 1983 | 9 | 0 |
| 1984 | 12 | 0 |
| 1985 | 7 | 0 |
| 1986 | 9 | 0 |
| 1987 | 18 | 0 |
| 1988 | 14 | 0 |
| 1989 | 13 | 0 |
| 1990 | 8 | 0 |
| 1991 | 9 | 0 |
| 1992 | 23 | 0 |
| 1993 | 26 | 0 |
| 1994 | 20 | 0 |
| 1995 | 20 | 0 |
| 1996 | 16 | 0 |
| 1997 | 29 | 0 |
| 1998 | 67 | 0 |
| 1999 | 56 | 0 |
| 2000 | 65 | 0 |
| 2001 | 47 | 9 |
| 2002 | 65 | 107 |
| 2003 | 45 | 155 |
| 2004 | 49 | 165 |
| 2005 | 43 | 164 |
| 2006 | 51 | 139 |
| 2007 | 49 | 142 |
| 2008 | 38 | 169 |
| 2009 | 78 | 189 |
| 2010 | 79 | 218 |
| 2011 | 87 | 227 |
| 2012 | 97 | 208 |
| 2013 | 108 | 196 |
| 2014 | 159 | 221 |
| 2015 | 165 | 281 |
| 2016 | 180 | 256 |
| 2017 | 182 | 266 |
| 2018 | 209 | 272 |
| 2019 | 194 | 271 |
| 2020 | 202 | 304 |
| 2021 | 198 | 311 |
| 2022 | 164 | 307 |
| 2023 | 164 | 350 |
| 2024 | 189 | 351 |
| 2025 | 198 | 257 |
| 2026 | 89 | 198 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Ambient temperature lipid particle storage systems and methods29 Sep 2026US 12,746,281 B2Ambient Biosciences, Inc.
- Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F15 Sep 2026US 12,734,229 B2Inventprise, LLC
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Compositions and methods for inducing immune tolerance8 Sep 2026US 12,728,155 B2Anokion SA
- Production of MHC II/CII complexes1 Sep 2026US 12,721,884 B2
- Antigen-specific physiologic dendritic cells for therapy8 Oct 2026US 2026/0306597 A1Emory University
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity737US 4,554,101 ANew York Blood Center, Inc. · 1985
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Immunogenic polysaccharide-protein conjugates208US 4,356,170 ACanadian Patents and Development Limited · 1982